Unnamed: 0 int64 0 350k | level_0 int64 0 351k | ApplicationNumber int64 9.75M 96.1M | ArtUnit int64 1.6k 3.99k | Abstract stringlengths 1 8.37k | Claims stringlengths 3 292k | abstract-claims stringlengths 68 293k | TechCenter int64 1.6k 3.9k |
|---|---|---|---|---|---|---|---|
900 | 900 | 15,322,675 | 1,615 | The present invention relates to an anhydrous composition comprising:
from 3% to 15% by weight of at least one lipophilic gelling agent; from 10% to 50% by weight of fillers including at least 5% by weight of a first filler and at least 5% by weight of a second filler different from the first; and from 40%... | 1. An anhydrous composition comprising: based on a total weight of the composition,
from 3% to 15% by weight of at least one lipophilic gelling agent; from 10% to 50% by weight of fillers including at least 5% by weight of a first filler and at least 5% by weight of a second filler different from the first; and from 40... | The present invention relates to an anhydrous composition comprising:
from 3% to 15% by weight of at least one lipophilic gelling agent; from 10% to 50% by weight of fillers including at least 5% by weight of a first filler and at least 5% by weight of a second filler different from the first; and from 40%... | 1,600 |
901 | 901 | 15,383,211 | 1,627 | Pharmaceutical compositions for treating, mitigating or preventing kidney stone disease, bladder stone disease or ureter stone disease are described, the compositions comprising a reducing agent capable of undergoing thiol-disulfide exchange with cystine to form a mixed disulfide and a citrate of an alkali metal or alk... | 1. A pharmaceutical composition for treating, mitigating or preventing kidney stone disease, bladder stone disease or ureter stone disease, the composition comprising:
(a) a therapeutically effective quantity of a first component, wherein the first component comprises at least one pharmaceutically acceptable reducing a... | Pharmaceutical compositions for treating, mitigating or preventing kidney stone disease, bladder stone disease or ureter stone disease are described, the compositions comprising a reducing agent capable of undergoing thiol-disulfide exchange with cystine to form a mixed disulfide and a citrate of an alkali metal or alk... | 1,600 |
902 | 902 | 15,900,544 | 1,623 | A process for preparing a composition (C 1 ) represented by the formula (I): HO—CH 2 —(CHOH) n —CH 2 —O-(G) x -H, in which G represents the remainder of a reducing sugar, n is an integer equal to 2, 3 or 4 and x, which indicates the mean degree of polymerization of the remainder G, represents a decimal number greater t... | 1. A process for preparing a composition (C2), said composition (C2) comprising, per 100% of its weight:
from 1% to 70% by weight of a polyol of formula (A1):
HO—CH2—(CHOH)n—CH2—OH (A1),
in which n is an integer equal to 2, 3 or 4;
from 25% to 98.9% by weight of a composition (C1) represented by the formula (I):
... | A process for preparing a composition (C 1 ) represented by the formula (I): HO—CH 2 —(CHOH) n —CH 2 —O-(G) x -H, in which G represents the remainder of a reducing sugar, n is an integer equal to 2, 3 or 4 and x, which indicates the mean degree of polymerization of the remainder G, represents a decimal number greater t... | 1,600 |
903 | 903 | 15,677,526 | 1,654 | Adsorptive media for chromatography, particularly ion-exchange chromatography, derived from a shaped fiber. In certain embodiments, the functionalized shaped fiber presents a fibrillated or ridged structure which greatly increases the surface area of the fibers when compared to ordinary fibers. Also disclosed herein is... | 1. A process for purifying a negatively-charged virus, comprising providing a sample containing negatively-charged virus; contacting said sample containing said negatively-charged virus with an axially compressed bed of cut nylon staple fiber media, wherein said cut fibers have a cross-section comprising a body region ... | Adsorptive media for chromatography, particularly ion-exchange chromatography, derived from a shaped fiber. In certain embodiments, the functionalized shaped fiber presents a fibrillated or ridged structure which greatly increases the surface area of the fibers when compared to ordinary fibers. Also disclosed herein is... | 1,600 |
904 | 904 | 15,411,337 | 1,651 | According to one embodiment, a microcapsule for selective catalysis of gases, the microcapsule comprising: a polymeric shell permeable to one or more target gases; and at least one biocatalyst disposed in an interior of the polymeric shell. In more embodiments, methods of forming such microcapsules include: emulsifying... | 1. A microcapsule for selective catalysis of gases, the microcapsule comprising:
a polymeric shell permeable to one or more target gases; and at least one biocatalyst disposed in an interior of the polymeric shell. 2. The microcapsule as recited in claim 1, comprising a buffer disposed in the interior of the polymeric ... | According to one embodiment, a microcapsule for selective catalysis of gases, the microcapsule comprising: a polymeric shell permeable to one or more target gases; and at least one biocatalyst disposed in an interior of the polymeric shell. In more embodiments, methods of forming such microcapsules include: emulsifying... | 1,600 |
905 | 905 | 14,964,297 | 1,627 | This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the NNRTI compound TMC278, suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment and prophylax... | 1. A method for the long-term treatment of HIV infection, comprising administering to a patient in need thereof by intramuscular or subcutaneous injection a pharmaceutical composition comprising a therapeutically effective amount of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (... | This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the NNRTI compound TMC278, suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment and prophylax... | 1,600 |
906 | 906 | 16,358,798 | 1,627 | Topical application of Delphinidin twice per day treats rosacea and maintains normal healthy skin in patients with rosacea. Delphinidin applied topically increases and nourishes collagen and promote healthy skin. | 1. A topical cream comprising Delphinidin in an amount effective to ameliorate dermal inflammation due to rosacea or lupus. 2. The topical cream of claim 1, comprising at least about 1% (w/w) Delphinidin. 3. The topical cream of claim 2, comprising at least about 10% (w/w) Delphinidin. 4. The topical cream of claim 1, ... | Topical application of Delphinidin twice per day treats rosacea and maintains normal healthy skin in patients with rosacea. Delphinidin applied topically increases and nourishes collagen and promote healthy skin.1. A topical cream comprising Delphinidin in an amount effective to ameliorate dermal inflammation due to ro... | 1,600 |
907 | 907 | 15,070,005 | 1,651 | The present disclosure provides the use of a phosphatidylcholine compound as a component of a media composition. The resulting media composition can be used for the cryopreservation of eukaryotic cells. The cryopreserved eukaryotic cells can be thawed and recovered for inoculation and/or growth in a media to reproduce ... | 1. A media composition, comprising:
(i) an aqueous solution including at least one cryopreservation agent, a cell suspension media, and a phosphatidylcholine; and, (ii) a eukaryotic cell. 2. The media composition of claim 1, wherein the cryopreservation agent is selected from the group consisting of glycerol, DMSO (dim... | The present disclosure provides the use of a phosphatidylcholine compound as a component of a media composition. The resulting media composition can be used for the cryopreservation of eukaryotic cells. The cryopreserved eukaryotic cells can be thawed and recovered for inoculation and/or growth in a media to reproduce ... | 1,600 |
908 | 908 | 14,547,771 | 1,628 | Methods of suppressing cachexia in a mammal with cancer comprising administering HDAC inhibitors are provided. Aspects include methods of administering an HDAC class 1 and 2b inhibitor in an amount effective to substantially maintain the mammal's weight compared to a mammal that does receive the HDAC class 1 and 2b inh... | 1. A method of suppressing cachexia in a mammal with cancer comprising administering a HDAC class 1 and 2b inhibitor to said mammal in an amount effective to substantially maintain the mammal's weight compared to a mammal that does not receive the HDAC class 1 and 2b inhibitor. 2. The method of claim 1, wherein the HDA... | Methods of suppressing cachexia in a mammal with cancer comprising administering HDAC inhibitors are provided. Aspects include methods of administering an HDAC class 1 and 2b inhibitor in an amount effective to substantially maintain the mammal's weight compared to a mammal that does receive the HDAC class 1 and 2b inh... | 1,600 |
909 | 909 | 15,313,512 | 1,613 | The instant disclosure provides embodiments of orally disintegrating tablet compositions that have rapid disintegrability in the oral cavity and comprise solid lipid particles enclosing at least one active ingredient to mask any unpleasant tastes associated with the active ingredient. Also provided is the process of pr... | 1. A pharmaceutical composition, comprising:
an orally disintegrating tablet comprising a disintegrant, a binder, and a plurality of solid lipid particles, said solid lipid particles comprising an active agent and a lipid matrix, wherein said binder is present in an amount of from 10 weight percent to 60 weight percent... | The instant disclosure provides embodiments of orally disintegrating tablet compositions that have rapid disintegrability in the oral cavity and comprise solid lipid particles enclosing at least one active ingredient to mask any unpleasant tastes associated with the active ingredient. Also provided is the process of pr... | 1,600 |
910 | 910 | 15,723,826 | 1,646 | A method of treating autoimmune diseases and transplant rejection, comprising the step of treating the autoimmune or transplant patient with an effective amount of SU-5416 is disclosed. | 1. A method of treating a patient with an autoimmune disease or inflammatory disorder comprising the step of:
(a) treating the patient with an effective amount of SU5416, wherein at least one symptom of disease is reduced or alleviated. 2. The method of claim 1, wherein the patient is treated when at least one symptom ... | A method of treating autoimmune diseases and transplant rejection, comprising the step of treating the autoimmune or transplant patient with an effective amount of SU-5416 is disclosed.1. A method of treating a patient with an autoimmune disease or inflammatory disorder comprising the step of:
(a) treating the patient ... | 1,600 |
911 | 911 | 15,107,206 | 1,616 | The present invention provides a method of preserving cut roses in the absence of a water supply. The method comprises: (a) cutting roses having a flower bud or a bloomed flower; and (b) packaging the cut roses in a container without immersing or inserting the stems in a hydration system. Instead, the cut roses are tre... | 1. -16. (canceled) 17. A flower shipment kit, comprising:
(a) a container defining an inner chamber; and (b) one or more cut roses contained within the inner chamber;
wherein flower buds or bloomed flowers of the one or more cut roses contain added plant hormone, selected from the group consisting of cytokinins, gibbe... | The present invention provides a method of preserving cut roses in the absence of a water supply. The method comprises: (a) cutting roses having a flower bud or a bloomed flower; and (b) packaging the cut roses in a container without immersing or inserting the stems in a hydration system. Instead, the cut roses are tre... | 1,600 |
912 | 912 | 14,644,608 | 1,628 | The present invention provides a method of treating depression disease in a patient comprising administering to a mucosal membrane of a patient an effective amount of a pharmaceutically acceptable composition comprising an effective amount of ketamine or dextromethorphan, or both ketamine and dextromethorphan, wherein ... | 1. A method of treating depression disease in a patient comprising:
administering to a mucosal membrane of a patient an effective amount of a composition comprising an effective amount of ketamine or dextromethorphan, or both, wherein said mucosal administration of said composition allows for the transmucosal absorptio... | The present invention provides a method of treating depression disease in a patient comprising administering to a mucosal membrane of a patient an effective amount of a pharmaceutically acceptable composition comprising an effective amount of ketamine or dextromethorphan, or both ketamine and dextromethorphan, wherein ... | 1,600 |
913 | 913 | 14,611,643 | 1,632 | A recombinant herpes virus showing high antitumor activity is provided. In particular, a recombinant herpes simplex virus that expresses an ICP6 gene under control of a tumor-specific promoter or tissue-specific promoter on the genome of the virus is provided. | 1-4. (canceled) 5. A recombinant herpes simplex virus comprising an endogenous ICP6 gene functionally linked to a tumor-specific promoter or tissue-specific promoter. 6. The recombinant herpes simplex virus according to claim 5, wherein the tumor-specific promoter or tissue-specific promoter is a promoter selected from... | A recombinant herpes virus showing high antitumor activity is provided. In particular, a recombinant herpes simplex virus that expresses an ICP6 gene under control of a tumor-specific promoter or tissue-specific promoter on the genome of the virus is provided.1-4. (canceled) 5. A recombinant herpes simplex virus compri... | 1,600 |
914 | 914 | 16,278,030 | 1,656 | The present invention provides a microorganism-derived soluble coenzyme-binding glucose dehydrogenase which catalyzes a reaction for oxidizing glucose in the presence of an electron acceptor, has an activity to maltose as low as 5% or less, and is inhibited by 1,10-phenanthroline. The invention also provides a method f... | 1-22. (canceled) 23. A biosensor for measuring glucose, comprising:
an electrode system comprising an action electrode and a counter electrode; and an enzymatic reaction layer in contact with the action electrode and/or the counter electrode, the enzymatic reaction layer comprising an electron acceptor and a soluble fl... | The present invention provides a microorganism-derived soluble coenzyme-binding glucose dehydrogenase which catalyzes a reaction for oxidizing glucose in the presence of an electron acceptor, has an activity to maltose as low as 5% or less, and is inhibited by 1,10-phenanthroline. The invention also provides a method f... | 1,600 |
915 | 915 | 14,332,865 | 1,616 | This invention relates to the use of the compound flutriafol for protecting plants and plant propagation material from Sudden Death Syndrome. The use comprises applying a composition comprising flutriafol to the soil from which the plant propagation material, a plant, part of a plant and/or plant organ grow or grows at... | 1. Use of flutriafol for controlling the causative agent of Sudden Death Syndrome (SDS) in a plant propagation material, a plant, part of a plant and/or plant organ, which comprises applying a composition comprising flutriafol to the soil from which the plant propagation material, a plant, part of a plant and/or plant ... | This invention relates to the use of the compound flutriafol for protecting plants and plant propagation material from Sudden Death Syndrome. The use comprises applying a composition comprising flutriafol to the soil from which the plant propagation material, a plant, part of a plant and/or plant organ grow or grows at... | 1,600 |
916 | 916 | 14,888,380 | 1,618 | The present invention relates to balloon catheter coated with an active agent and a shellac alkali salt, preferably shellac ammonium salt. Moreover the present invention relates to a method for coating catheter balloons with a pharmacological active agent and an aqueous solution of shellac. | 1. A balloon catheter comprising a coating with an active agent and a water soluble shellac salt. 2. Balloon catheter according to claim 1, wherein the water soluble shellac salt is a shellac ammonium salt. 3. Balloon catheter according to claim 1 or 2, wherein the coating comprises a concentration gradient of the acti... | The present invention relates to balloon catheter coated with an active agent and a shellac alkali salt, preferably shellac ammonium salt. Moreover the present invention relates to a method for coating catheter balloons with a pharmacological active agent and an aqueous solution of shellac.1. A balloon catheter compris... | 1,600 |
917 | 917 | 15,434,258 | 1,612 | A method for applying a composition to teeth and a dispenser for dispensing a composition. The method of the present invention is directed to the storage and dispensing of a composition. During storage and subsequent use the composition in the storage chamber must be maintained segregated from the applicator surface. T... | 1. A method of applying a peroxide containing tooth whitening composition comprising:
a. providing said tooth whitening composition in a housing sealed at one end and having an application means at another end, the application means comprising an applicator surface having an aperture therein at an end of a channel, sai... | A method for applying a composition to teeth and a dispenser for dispensing a composition. The method of the present invention is directed to the storage and dispensing of a composition. During storage and subsequent use the composition in the storage chamber must be maintained segregated from the applicator surface. T... | 1,600 |
918 | 918 | 15,542,005 | 1,636 | Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided. | 1-158. (canceled) 159. A composition comprising:
(a) a viral vector comprising a nucleotide sequence encoding a MUC1 antigen; (b) a viral vector comprising a nucleotide sequence encoding a Brachyury antigen; and (c) a viral vector comprising a nucleotide sequence encoding a CEA antigen. 160. The composition of claim 15... | Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.1-158. (canceled) 159. A composition comprising:
(a) a viral vector comprising a nucleotide sequence enco... | 1,600 |
919 | 919 | 15,170,337 | 1,653 | Compositions for topical administration to a urogenital area and/or in a vagina are disclosed. The compositions includes a therapeutically effective amount of a selective estrogen receptor modulator (SERM), an intracellular carrier for carrying the SERM into a cell, and a therapeutically effective amount of a cellular ... | 1. A composition for topical administration in a urogenital area and/or a vagina comprising:
a therapeutically effective amount of a selective estrogen receptor modulator (SERM); an intracellular carrier for carrying the SERM into a cell; and a therapeutically effective amount of a cellular anti-inflammatory agent. 2. ... | Compositions for topical administration to a urogenital area and/or in a vagina are disclosed. The compositions includes a therapeutically effective amount of a selective estrogen receptor modulator (SERM), an intracellular carrier for carrying the SERM into a cell, and a therapeutically effective amount of a cellular ... | 1,600 |
920 | 920 | 16,061,121 | 1,615 | A synthetic nutritional composition comprising a phospholipid and/or a metabolic precursor and/or metabolite thereof for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cogn... | 1. A method to promote, support or optimise de novo myelination, and/or brain structure, and/or brain connectivity, and/or intellectual potential, and/or cognitive potential, and/or learning potential and cognitive functioning in a subject, in particular a formula fed subject, wherein, brain structure refers to the amo... | A synthetic nutritional composition comprising a phospholipid and/or a metabolic precursor and/or metabolite thereof for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cogn... | 1,600 |
921 | 921 | 15,430,729 | 1,619 | Compositions and methods are provided for improving canine exercise performance. The compositions are pre-exercise supplements that generally comprise (a) about 35% to about 60% protein or amino acids, comprising one or more structural proteins, one or more bioavailable proteins and one or more branched chain amino aci... | 1. A canine pre-exercise supplement comprising:
a. about 35% to about 60% protein or amino acids, comprising one or more structural proteins, one or more bioavailable proteins and one or more branched chain amino acids; b. about 20% to about 38% fat, comprising at least one source of medium chain triglycerides; and c. ... | Compositions and methods are provided for improving canine exercise performance. The compositions are pre-exercise supplements that generally comprise (a) about 35% to about 60% protein or amino acids, comprising one or more structural proteins, one or more bioavailable proteins and one or more branched chain amino aci... | 1,600 |
922 | 922 | 14,969,798 | 1,644 | The present invention relates to the general field of treatment and prevention of diseases involving an inflammatory condition, namely sepsis or infectious or viral diseases as well as diseases requiring for the treatment of immunosuppressive activity namely autoimmune diseases and graft rejection. In particular, the i... | 1-15. (canceled) 16. A method of treating an inflammatory condition in a patient in need thereof, comprising the step of
administering to said patient a therapeutic amount of an inhibitor of activity or formation of a PP1/GADD34 complex to treat said inflammatory condition. 17. The method of claim 16, wherein said infl... | The present invention relates to the general field of treatment and prevention of diseases involving an inflammatory condition, namely sepsis or infectious or viral diseases as well as diseases requiring for the treatment of immunosuppressive activity namely autoimmune diseases and graft rejection. In particular, the i... | 1,600 |
923 | 923 | 10,097,106 | 1,644 | Novel compounds carrying ligands capable of ligating to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as in v... | 1. A MHC molecule construct comprising
a carrier molecule having attached thereto one or more MHC molecules, said MHC molecules being attached to the carrier molecule either directly or via one or more binding entities. 2. The MHC molecule construct according to claim 1, wherein the MHC molecule is a vertebrate MHC mol... | Novel compounds carrying ligands capable of ligating to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as in v... | 1,600 |
924 | 924 | 14,994,521 | 1,619 | Aerosol compositions propelled by compressed gas providing enhanced intensity of one or more active components (e.g., fragrance, malodor counteractant, insecticide, disinfectant, or antimicrobial) over an extended period of time in the environment of use consistently over the life of the product. This is provided by a ... | 1. Article of manufacture for aerosol treatment of air and surfaces comprising
(a) a dispensing device comprising a plastic container adapted to hold a treating composition and a compressed gas propellant, wherein said plastic container is made of polyethyleneterephthalate (PET); (b) the treating composition comprising... | Aerosol compositions propelled by compressed gas providing enhanced intensity of one or more active components (e.g., fragrance, malodor counteractant, insecticide, disinfectant, or antimicrobial) over an extended period of time in the environment of use consistently over the life of the product. This is provided by a ... | 1,600 |
925 | 925 | 14,848,990 | 1,641 | Disclosed is a method for preparing a composition enriched for receptors (typically molecular impringet polymers, MIPs) that bind an agent, where said receptors each specifically bind at least two discrete sites on said agent, by subjecting a sample of receptors to a first step of affinity purification with the agent w... | 1. (canceled) 2. (canceled) 3. A method for treatment, amelioration or prophylaxis of a disease selected from the group consisting of hyperphenylalaninemia (HPA), alcaptonuria (black urine disease), tyrosinemia, hypertyrosinemia, myasthenia gravis, histidinemia, urocanic aciduria, maple syrup urine disease (MSUD), isov... | Disclosed is a method for preparing a composition enriched for receptors (typically molecular impringet polymers, MIPs) that bind an agent, where said receptors each specifically bind at least two discrete sites on said agent, by subjecting a sample of receptors to a first step of affinity purification with the agent w... | 1,600 |
926 | 926 | 14,701,002 | 1,642 | A method for the in vitro diagnosis of colorectal cancer by determining the presence of the Ezrin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer using at least one anti-Ezrin monoclonal antibody directed against an Ezrin epitope chosen from the epitopes of sequence SEQ ID... | 1. A monoclonal antibody directed against an epitope selected from the group consisting of SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4+SEQ ID No.5, SEQ ID No.6+SEQ ID No.7, and SEQ ID No.8. 2. The monoclonal antibody of claim 1 directed against the epitope of SEQ ID No.1. 3. The monoclonal antibody of claim 1 di... | A method for the in vitro diagnosis of colorectal cancer by determining the presence of the Ezrin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer using at least one anti-Ezrin monoclonal antibody directed against an Ezrin epitope chosen from the epitopes of sequence SEQ ID... | 1,600 |
927 | 927 | 13,981,706 | 1,619 | The present invention relates to microparticles comprising a gel body, wherein the gel body comprises a synthetic polymer and a drug, wherein the microparticles have an average diameter in the range 40 to 1500 μm, wherein the polymer is cross-linked by groups comprising disulfide linkages and is in the form of a hydrog... | 1. Microparticles comprising a gel body, wherein the gel body comprises a synthetic polymer and a drug, wherein the microparticles have an average diameter in the range 40 to 1500 μm, wherein the polymer is cross-linked by groups comprising disulfide linkages and is in the form of a hydrogel. 2. Microparticles accordin... | The present invention relates to microparticles comprising a gel body, wherein the gel body comprises a synthetic polymer and a drug, wherein the microparticles have an average diameter in the range 40 to 1500 μm, wherein the polymer is cross-linked by groups comprising disulfide linkages and is in the form of a hydrog... | 1,600 |
928 | 928 | 15,756,146 | 1,612 | Anhydrous oral care compositions and methods for preventing phase separation in the anhydrous oral care composition are disclosed. The oral care composition may include an orally acceptable vehicle, a thickening system, and a whitening agent. The orally acceptable vehicle may include propylene glycol, and the thickenin... | 1. An anhydrous oral care composition, comprising:
an orally acceptable vehicle, the orally acceptable vehicle comprising propylene glycol; a thickening system, the thickening system comprising a polymeric thickener, wherein the polymeric thickener is a copolymer of 2-acrylamidomethylpropanesulphonic acid or a salt the... | Anhydrous oral care compositions and methods for preventing phase separation in the anhydrous oral care composition are disclosed. The oral care composition may include an orally acceptable vehicle, a thickening system, and a whitening agent. The orally acceptable vehicle may include propylene glycol, and the thickenin... | 1,600 |
929 | 929 | 15,257,079 | 1,618 | The present invention relates to a process for the production of abuse-proofed, thermoformed dosage forms containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of a... | 1. A process for the production of a solid pharmaceutic dosage forms with at least reduced potential for abuse, comprising:
a) a formulation mixture containing at least one active ingredient with potential for abuse, at least one synthetic or natural polymer (C), which exhibits a breaking strength of at least 500 N, an... | The present invention relates to a process for the production of abuse-proofed, thermoformed dosage forms containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of a... | 1,600 |
930 | 930 | 14,438,962 | 1,631 | Provided is a brain activity training apparatus for training to cause a change in correlation of connectivity among brain regions, utilizing measured correlations of connections among brains regions as feedback information. From measured data of resting-state functional connectivity MRI of a healthy group and a patient... | 1. A brain activity training apparatus, comprising:
a brain activity detecting device for time-sequentially detecting signals indicative of brain activities at a plurality of prescribed regions in a brain of a first subject; and a storage device for storing information that specifies a discriminator generated from sign... | Provided is a brain activity training apparatus for training to cause a change in correlation of connectivity among brain regions, utilizing measured correlations of connections among brains regions as feedback information. From measured data of resting-state functional connectivity MRI of a healthy group and a patient... | 1,600 |
931 | 931 | 15,309,566 | 1,651 | A method of treating a wound including applying a wound care treatment to the wound, the wound care treatment including a preparation composed of morselized amnion tissue and amniotic fluid cells adsorbed to a porous collagen matrix and optionally, glycosaminoglycan. The morselized amnion tissue includes organized amni... | 1. A method of treating a wound comprising:
providing a first preparation including amnion tissue and amniotic fluid cells, wherein the amnion tissue is morselized amnion tissue and includes organized amniotic extracellular matrix (ECM), amniotic tissue cells and growth factors contained within the ECM and amniotic tis... | A method of treating a wound including applying a wound care treatment to the wound, the wound care treatment including a preparation composed of morselized amnion tissue and amniotic fluid cells adsorbed to a porous collagen matrix and optionally, glycosaminoglycan. The morselized amnion tissue includes organized amni... | 1,600 |
932 | 932 | 15,307,143 | 1,617 | The present invention relates to a process for producing microcapsules which contain a shell and a core of a liquid water-insoluble material, where
(a) a premix (I) is prepared from water and a protective colloid; (b) a further premix (II) is prepared from the water-insoluble material and at least bifunctional i... | 1-15. (canceled) 16: A process for producing microcapsules which contain a shell and a core of a liquid water-insoluble material, where
(a) a premix (I) is prepared from water and a protective colloid; (b) a further premix (II) is prepared from the water-insoluble material and at least bifunctional isocyanate (A) or a ... | The present invention relates to a process for producing microcapsules which contain a shell and a core of a liquid water-insoluble material, where
(a) a premix (I) is prepared from water and a protective colloid; (b) a further premix (II) is prepared from the water-insoluble material and at least bifunctional i... | 1,600 |
933 | 933 | 11,585,607 | 1,633 | Methods of producing a protein in cell culture comprising an anti-senescence compound, such as the antioxidant carnosine, are provided. According to teachings of the present invention, cells grown in a cell culture medium comprising an anti-senescence compound exhibit increased viability and productivity. Furthermore, ... | 1. A method of producing a protein in cell culture comprising steps of:
culturing mammalian cells that contain a gene encoding a protein of interest, which gene is expressed under conditions of cell culture, in a cell culture medium comprising an anti-senescence compound; and maintaining the culture under conditions ... | Methods of producing a protein in cell culture comprising an anti-senescence compound, such as the antioxidant carnosine, are provided. According to teachings of the present invention, cells grown in a cell culture medium comprising an anti-senescence compound exhibit increased viability and productivity. Furthermore, ... | 1,600 |
934 | 934 | 14,443,118 | 1,631 | The present invention aims to provide a data analysis apparatus capable of clustering appropriately even when there is an exceptional datum resulted from an experimental error and the like. In the data analysis apparatus according to the invention, a cluster range parameter for stretching a cluster boundary is determin... | 1. A data analysis apparatus for clustering and analyzing sample data, having:
a sample data input unit receiving sample data, an experimental error data input unit receiving an experimental error datum which describes information about an experimental error of the sample data, a computing unit clustering the sample da... | The present invention aims to provide a data analysis apparatus capable of clustering appropriately even when there is an exceptional datum resulted from an experimental error and the like. In the data analysis apparatus according to the invention, a cluster range parameter for stretching a cluster boundary is determin... | 1,600 |
935 | 935 | 15,834,953 | 1,654 | The present disclosure relates to pharmaceutical compositions for mammalian consumption containing essential fatty acids, protein, vitamins and choline, or combinations thereof, so constituted to optimize absorption and/or transport and/or efficiency of the co-ingredients of the composition. The pharmaceutical composit... | 1. A composition comprising:
about 10 to about 1500 mg of an essential fatty acid selected from the group consisting of EPA, DHA and ALA; and about 10 to about 33,000 μg of a cobalamin binding protein. 2. The composition of claim 1, wherein the essential fatty acid is DHA. 3. The composition of claim 2, wherein the sou... | The present disclosure relates to pharmaceutical compositions for mammalian consumption containing essential fatty acids, protein, vitamins and choline, or combinations thereof, so constituted to optimize absorption and/or transport and/or efficiency of the co-ingredients of the composition. The pharmaceutical composit... | 1,600 |
936 | 936 | 14,360,503 | 1,617 | A delivery device for a active agent comprises nanoparticles based on a biopolymer such as starch. The delivery device may also be in the form of an aptamer-biopolymer-active agent conjugate wherein the aptamer targets the device for the treatment of specific disorders, such as cancer. The delivery device survives for ... | 1. A delivery system comprising,
nanoparticles comprising a mass of crosslinked biopolymers, wherein the degree of crosslinking of the biopolymers provides a release profile of an active agent from the nanoparticle within a predetermined range of release profiles. 2. A delivery system comprising, nanoparticles comprisi... | A delivery device for a active agent comprises nanoparticles based on a biopolymer such as starch. The delivery device may also be in the form of an aptamer-biopolymer-active agent conjugate wherein the aptamer targets the device for the treatment of specific disorders, such as cancer. The delivery device survives for ... | 1,600 |
937 | 937 | 15,527,500 | 1,656 | Disclosed is a method of producing high-concentration collagen for use as a medical material, including: washing tissue of a mammal; subjecting the washed tissue to crushing and immersion in ethyl alcohol; subjecting the tissue to enzymatic treatment with stirring in purified water containing phosphoric acid and pepsin... | 1. A method of producing high-concentration collagen for use as a medical material, comprising:
washing tissue of a mammal; subjecting the washed tissue to crushing and immersion in ethyl alcohol; subjecting the tissue to enzymatic treatment with stirring in purified water containing phosphoric acid and pepsin; adding ... | Disclosed is a method of producing high-concentration collagen for use as a medical material, including: washing tissue of a mammal; subjecting the washed tissue to crushing and immersion in ethyl alcohol; subjecting the tissue to enzymatic treatment with stirring in purified water containing phosphoric acid and pepsin... | 1,600 |
938 | 938 | 16,278,019 | 1,656 | The present invention provides a microorganism-derived soluble coenzyme-binding glucose dehydrogenase which catalyzes a reaction for oxidizing glucose in the presence of an electron acceptor, has an activity to maltose as low as 5% or less, and is inhibited by 1,10-phenanthroline. The invention also provides a method f... | 1-22. (canceled) 23. A biosensor for measuring glucose, comprising:
an electrode system comprising an action electrode and a counter electrode; and an enzymatic reaction layer in contact with the action electrode and/or the counter electrode, the enzymatic reaction layer comprising an electron acceptor and a soluble fl... | The present invention provides a microorganism-derived soluble coenzyme-binding glucose dehydrogenase which catalyzes a reaction for oxidizing glucose in the presence of an electron acceptor, has an activity to maltose as low as 5% or less, and is inhibited by 1,10-phenanthroline. The invention also provides a method f... | 1,600 |
939 | 939 | 15,215,804 | 1,617 | A chewable pharmaceutical product comprises a matrix comprising: a binder, a bulking agent, a lubricant, a humectant, an emulsifier, and optionally a flavoring, wherein the binder comprises one or more maltitol syrups, which are present in the pharmaceutical product in an amount in the range of 60-70% by weight; and co... | 1. A chewable pharmaceutical product comprising:
a matrix comprising: a binder, a bulking agent, a lubricant, a humectant, an emulsifier, and optionally one or more of a flavoring, a coloring, and an antioxidant, wherein the binder comprises one or more maltitol syrups that are present in the pharmaceutical product in ... | A chewable pharmaceutical product comprises a matrix comprising: a binder, a bulking agent, a lubricant, a humectant, an emulsifier, and optionally a flavoring, wherein the binder comprises one or more maltitol syrups, which are present in the pharmaceutical product in an amount in the range of 60-70% by weight; and co... | 1,600 |
940 | 940 | 15,095,702 | 1,627 | A medication comprising tetrahydropyridoethers for use in the treatment of AMD. | 1. A method of removing lipofuscin accumulated in retinal pigment endothelium cells in a treatment of a subject, comprising: administering to the subject in need of such treatment a medication comprising a compound according to the following formula I as active ingredient in suitable amount,
in which
R1 is me... | A medication comprising tetrahydropyridoethers for use in the treatment of AMD.1. A method of removing lipofuscin accumulated in retinal pigment endothelium cells in a treatment of a subject, comprising: administering to the subject in need of such treatment a medication comprising a compound according to the following... | 1,600 |
941 | 941 | 15,087,066 | 1,617 | The disclosure relates to compositions and methods for improving the appearance of the skin. Compositions comprise comprising (A) (a) at least one vinyl-terminated polysiloxane and at least one hydride-functionalized polysiloxane, and (b) at least one filler; and (B) (a) at least one vinyl-terminated polysiloxane; (b) ... | 1. A skin tightening composition comprising:
(A) (a) at least one vinyl-terminated polysiloxane and at least one hydride-functionalized polysiloxane;
(b) at least one filler; and
(B) (a) at least one vinyl-terminated polysiloxane;
(c) at least one filler; and
(d) at least one at least one metal catalyst,
wherein the ... | The disclosure relates to compositions and methods for improving the appearance of the skin. Compositions comprise comprising (A) (a) at least one vinyl-terminated polysiloxane and at least one hydride-functionalized polysiloxane, and (b) at least one filler; and (B) (a) at least one vinyl-terminated polysiloxane; (b) ... | 1,600 |
942 | 942 | 16,354,739 | 1,648 | The invention relates to VLP derived from human polyoma virus loaded with a drug (cargo) as a drug delivery system for transporting said drug into the CNS, in particular of living humans. | 1. A method of treating a subject having a central nervous system (CNS) disease or a neurological, neuronal or neurodegenerative disorder, the method comprising:
intravenously administering a drug delivery system composed of VLP loaded with a drug into a subject, wherein, the VLP crosses the blood-brain barrier (BBB) o... | The invention relates to VLP derived from human polyoma virus loaded with a drug (cargo) as a drug delivery system for transporting said drug into the CNS, in particular of living humans.1. A method of treating a subject having a central nervous system (CNS) disease or a neurological, neuronal or neurodegenerative di... | 1,600 |
943 | 943 | 14,633,067 | 1,618 | The present invention relates to a method for preparing a 2-fluoropurine marked with the radioisotope 18 F comprising a fluorination step for a 2-nitropurine derivative. The present invention comprises a 2-fluoropurine derivative marked with the radioisotope 18 F which can be obtained by or during a method according ... | 1-22. (canceled) 23. A method for performing PET imaging studies in a subject comprising administering to the subject a fludarabine marked with the radioisotope 18F of the formula (B) or one of its salts
and detecting said marked fludarabine. 24. The method according to claim 23, wherein PET imaging studies a... | The present invention relates to a method for preparing a 2-fluoropurine marked with the radioisotope 18 F comprising a fluorination step for a 2-nitropurine derivative. The present invention comprises a 2-fluoropurine derivative marked with the radioisotope 18 F which can be obtained by or during a method according ... | 1,600 |
944 | 944 | 15,515,857 | 1,617 | An encapsulated perfume composition in the form of a slurry comprising one or more core-shell capsules, dispersed in an aqueous dispersing medium, wherein the core contains a perfume and the shell contains a polyurea resin, and wherein the capsules are in the form of a stable suspension having a viscosity of up to 3000... | 1. An encapsulated perfume composition in the form of a slurry comprising one or more core-shell capsules, each having a core and a shell, dispersed in an aqueous dispersing medium, wherein the core contains a perfume and the shell contains a polyurea resin, and wherein the capsules are in the form of a stable suspensi... | An encapsulated perfume composition in the form of a slurry comprising one or more core-shell capsules, dispersed in an aqueous dispersing medium, wherein the core contains a perfume and the shell contains a polyurea resin, and wherein the capsules are in the form of a stable suspension having a viscosity of up to 3000... | 1,600 |
945 | 945 | 14,865,257 | 1,615 | The present invention relates to personal care compositions comprising malodor reduction compositions and methods of making and using such personal care compositions. Such personal care compositions comprising the malodor control technologies disclosed herein provide malodor control without leaving an undesirable scent... | 1. A personal care composition comprising, based on total composition weight,
a) a sum total of from about 0.0001% to about 2%, preferably from about 0.0001% to about 0.75%, more preferably from about 0.001% to about 0.5%, most preferably from about 0.007% to about 0.25% of 1 or more malodor reduction materials, prefer... | The present invention relates to personal care compositions comprising malodor reduction compositions and methods of making and using such personal care compositions. Such personal care compositions comprising the malodor control technologies disclosed herein provide malodor control without leaving an undesirable scent... | 1,600 |
946 | 946 | 15,708,205 | 1,615 | The present invention relates to personal care compositions comprising malodor reduction compositions and methods of making and using such personal care compositions. Such personal care compositions comprising the malodor control technologies disclosed herein provide malodor control without leaving an undesireable scen... | 1. A personal care composition comprising, based on total composition weight,
a) a sum total of from about 0.0001% to about 2%, preferably from about 0.0001% to about 0.75%, more preferably from about 0.001% to about 0.5%, most preferably from about 0.007% to about 0.25% of 1 or more malodor reduction materials, prefer... | The present invention relates to personal care compositions comprising malodor reduction compositions and methods of making and using such personal care compositions. Such personal care compositions comprising the malodor control technologies disclosed herein provide malodor control without leaving an undesireable scen... | 1,600 |
947 | 947 | 12,663,848 | 1,626 | Disclosed is a method for protecting an animal from a parasitic invertebrate pest comprising treating an animal orally or by injection with a pesticidally effective amount of a compound of Formula 1,
wherein
R 1 is hal... | 1. A method for protecting an animal from a parasitic invertebrate pest comprising orally or parenterally administering to the animal a pesticidally effective amount of a compound of Formula 1, an N-oxide or a salt thereof
wherein
R1 is halogen, C1-C3 haloalkyl or C1-C3 haloalkoxy;
R2 is H, halogen, C1-C3 al... | Disclosed is a method for protecting an animal from a parasitic invertebrate pest comprising treating an animal orally or by injection with a pesticidally effective amount of a compound of Formula 1,
wherein
R 1 is hal... | 1,600 |
948 | 948 | 16,149,759 | 1,611 | Core-shell capsules comprising a fragrance-containing core and a shell formed around said core, wherein the shell is formed of polycarboxylic acid having a molecular weight of 1,000 to 10,000,000 Daltons | 1. (canceled) 2. (canceled) 3. (canceled) 4. (canceled) 5. (canceled) 6. (canceled) 7. (canceled) 8. (canceled) 9. (canceled) 10. (canceled) 11. (canceled) 12. (canceled) 13. (canceled) 14. A method of encapsulation of a beneficial agent, comprising the steps of:
a) dispersing oil droplets comprising said beneficial ag... | Core-shell capsules comprising a fragrance-containing core and a shell formed around said core, wherein the shell is formed of polycarboxylic acid having a molecular weight of 1,000 to 10,000,000 Daltons1. (canceled) 2. (canceled) 3. (canceled) 4. (canceled) 5. (canceled) 6. (canceled) 7. (canceled) 8. (canceled) 9. (c... | 1,600 |
949 | 949 | 15,568,244 | 1,632 | Described herein are vectors, such as adeno-associated virus (AAV) vectors, and recombinant AAV expressing Smad7. The disclosed AAV vectors and rAAV can be used for therapeutic applications in the treatment and amelioration of muscle wasting, cardiac and/or skeletal muscle wasting associated with cancer cachexia. | 1. A composition comprising a Smad7 gene or cDNA in a recombinant adeno-assisted virus (rAAV) construct, wherein the rAAV construct provides expression of the Smad7 gene or cDNA in muscle cells. 2. The composition of claim 1, wherein the rAAV construct is serotype 6 (rAAV6), serotype 8 (rAAV8), or serotype 9 (rAAV9). 3... | Described herein are vectors, such as adeno-associated virus (AAV) vectors, and recombinant AAV expressing Smad7. The disclosed AAV vectors and rAAV can be used for therapeutic applications in the treatment and amelioration of muscle wasting, cardiac and/or skeletal muscle wasting associated with cancer cachexia.1. A c... | 1,600 |
950 | 950 | 15,948,359 | 1,628 | in which R1, R2, R3, R4, R5, R6, X, and a are defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are a pharmaceutical composition comprising a compound or salt thereof of Formula (I) and a method of treating a disease which benefits from the modulation of the vitamin D receptor, such as a bon... | 1. A compound of Formula (I)
wherein
R1 is ═CH2; or
R1 and the carbon to which it is bonded together form a cyclopropyl group;
R4 and R5 are the same or different and each is selected from the group consisting of H, C1-12 alkyl, hydroxyl, C1-12 alkoxy, and halo;
wherein said C1-C12 alkyl and said C1-C12 alko... | in which R1, R2, R3, R4, R5, R6, X, and a are defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are a pharmaceutical composition comprising a compound or salt thereof of Formula (I) and a method of treating a disease which benefits from the modulation of the vitamin D receptor, such as a bon... | 1,600 |
951 | 951 | 15,596,529 | 1,658 | Hydrogel compositions and methods of using hydrogel compositions are disclosed. Advantageously, the hydrogel compositions offer the ability to promote cellular expansion and/or cellular differentiation of various cells. | 1. A hydrogel composition comprising an 8-arm, 20 kDa polyethylene glycol functionalized with norbornene, a crosslinking peptide, and a cell adhesion peptide. 2. The hydrogel composition of claim 1 comprising at least 1 mM cell adhesion peptide selected from the group consisting of CRGDS (SEQ ID NO: 2), Acetylated-GCYG... | Hydrogel compositions and methods of using hydrogel compositions are disclosed. Advantageously, the hydrogel compositions offer the ability to promote cellular expansion and/or cellular differentiation of various cells.1. A hydrogel composition comprising an 8-arm, 20 kDa polyethylene glycol functionalized with norborn... | 1,600 |
952 | 952 | 12,850,269 | 1,653 | The claimed subject matter comprises a device to collect and preserve cells comprising of: (1) a collection container comprised of a tube having an open end and a closed end, a closure in the open end of the tube, a vacuum drawn to a predetermined level inside the container; and (2) compounds including an anticoagulant... | 1. A method of preserving biological specimens for disease diagnosis comprising:
providing a tube having an open end and a closed end; preloading compounds including: a fixative agent into said tube, said fixative agent capable of stabilizing abnormal cells such as cancer cells; placing a biological specimen containing... | The claimed subject matter comprises a device to collect and preserve cells comprising of: (1) a collection container comprised of a tube having an open end and a closed end, a closure in the open end of the tube, a vacuum drawn to a predetermined level inside the container; and (2) compounds including an anticoagulant... | 1,600 |
953 | 953 | 14,994,913 | 1,648 | The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for t... | 1. A method for stimulating an anti-influenza immune response in a subject comprising administering an effective amount of a pharmaceutical composition comprising a mRNA that encodes an influenza virus antigen to the subject. 2. The method of claim 1, wherein the influenza virus antigen is an influenza virus surface an... | The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for t... | 1,600 |
954 | 954 | 15,744,322 | 1,643 | The present invention provides a method for treating a tumor comprising administering an effective amount of an antibody which specifically binds to human CC chemokine receptor 4, human epidermal growth factor receptor 2, human CD20, or epidermal growth factor receptor, and an indoleamine 2,3-dioxygenase inhibitor to a... | 1-210. (canceled) 211. A method for treating a tumor comprising administering an effective amount of
(i) (a) an antibody which specifically binds to human CC chemokine receptor 4, human epidermal growth factor receptor 2, human CD20, or epidermal growth factor receptor, or (b) an antibody which specifically binds to hu... | The present invention provides a method for treating a tumor comprising administering an effective amount of an antibody which specifically binds to human CC chemokine receptor 4, human epidermal growth factor receptor 2, human CD20, or epidermal growth factor receptor, and an indoleamine 2,3-dioxygenase inhibitor to a... | 1,600 |
955 | 955 | 14,897,794 | 1,617 | The present invention encompasses methods of improving reproductive and respiratory health. | 1. A method for improving the per cycle pregnancy rate for maiden or barren equine mares and/or reducing the post-breeding inflammatory response of an equine mare, the method comprising administering a composition comprising Composition A at a daily dose of between 4-7 g per 110 lbs of body weight at least 10 days befo... | The present invention encompasses methods of improving reproductive and respiratory health.1. A method for improving the per cycle pregnancy rate for maiden or barren equine mares and/or reducing the post-breeding inflammatory response of an equine mare, the method comprising administering a composition comprising Comp... | 1,600 |
956 | 956 | 14,894,426 | 1,633 | The present invention relates to methods for developing engineered T-cells for immunotherapy and more specifically to methods for modifying T-cells by inactivating at immune checkpoint genes, preferably at least two selected from different pathways, to increase T-cell immune activity. This method involves the use of sp... | 1) A method of preparing T-cell(s) for immunotherapy comprising:
(a) modifying T-cell(s) by inactivating at least two genes encoding immune checkpoint proteins; and (b) expanding said cell(s). 2) The method of claim 1 comprising:
(a) modifying T-cell(s) by introducing into said T-cell(s) at least one rare-cutting endon... | The present invention relates to methods for developing engineered T-cells for immunotherapy and more specifically to methods for modifying T-cells by inactivating at immune checkpoint genes, preferably at least two selected from different pathways, to increase T-cell immune activity. This method involves the use of sp... | 1,600 |
957 | 957 | 14,414,368 | 1,627 | The present invention encompasses methods of treating a subject who has been diagnosed as having a tic disorder or a movement disorder. The tic disorder can be Tourette's Syndrome, and the methods can include the steps of: (a) identifying a subject in need of treatment; and (b) administering to the subject a therapeuti... | 1. (canceled) 2. A method of treating a subject diagnosed as having a tic disorder, the method comprising:
(a) identifying a subject in need of treatment; and (b) administering to the subject a therapeutically effective amount of a composition comprising a D1/D5 receptor antagonist, a D1/D5 receptor partial agonist, or... | The present invention encompasses methods of treating a subject who has been diagnosed as having a tic disorder or a movement disorder. The tic disorder can be Tourette's Syndrome, and the methods can include the steps of: (a) identifying a subject in need of treatment; and (b) administering to the subject a therapeuti... | 1,600 |
958 | 958 | 15,726,555 | 1,615 | The present disclosure provides a method of positioning an implant in a patient. The method includes inserting a deflated biodegradable balloon into a joint of the patient, wherein the biodegradable balloon is wedged between at least one of bone and soft tissue in the joint of the patient. The biodegradable balloon is ... | 1. A method of positioning an implant in a patient, the method comprising:
endoscopically inserting a deflated biodegradable balloon into the shoulder joint of the patient, wherein the biodegradable balloon is wedged between at least one of bone and soft tissue in the shoulder joint of the patient; and inflating the bi... | The present disclosure provides a method of positioning an implant in a patient. The method includes inserting a deflated biodegradable balloon into a joint of the patient, wherein the biodegradable balloon is wedged between at least one of bone and soft tissue in the joint of the patient. The biodegradable balloon is ... | 1,600 |
959 | 959 | 12,935,077 | 1,653 | The invention relates to the treatment of chronic stroke, traumatic brain injury, and neurodegenerative disorders using umbilical cord blood cells. | 1. A method for treating chronic stroke comprising
intraparenchymally administering, to a brain of a human subject who has experienced a stroke, an isolated umbilical cord blood cell population enriched in CD34+, CD133+, or CD34+/CD133+ cells, wherein the isolated umbilical cord blood cell population is administered mo... | The invention relates to the treatment of chronic stroke, traumatic brain injury, and neurodegenerative disorders using umbilical cord blood cells.1. A method for treating chronic stroke comprising
intraparenchymally administering, to a brain of a human subject who has experienced a stroke, an isolated umbilical cord b... | 1,600 |
960 | 960 | 14,889,686 | 1,633 | The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This m... | 1) A method of preparing T-cell(s) for immunotherapy comprising:
(a) modifying T-cell(s) by inactivating at least:
a first gene encoding a immune checkpoint protein, and
a second gene encoding a component of the T-cell receptor (TCR); and
(b) expanding said T-cell(s). 2) The method of claim 1 comprising modifying T-ce... | The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This m... | 1,600 |
961 | 961 | 15,514,833 | 1,654 | The invention relates to a method for peptide synthesis, wherein said method comprises the steps of reacting a first amino acid or a first peptide with an α-amine protected second amino acid in a solvent selected from the group consisting of water, alcohol, and a mixture of water and alcohol, and removing the α-amine p... | 1. A method of forming protecting groups on functional groups during water based peptide synthesis, the method comprising using a protective agent,
wherein the protective agent comprises a) a backbone structure, b) at least one water-solubility enhancing functional group and c) at least one reactive group, wherein the ... | The invention relates to a method for peptide synthesis, wherein said method comprises the steps of reacting a first amino acid or a first peptide with an α-amine protected second amino acid in a solvent selected from the group consisting of water, alcohol, and a mixture of water and alcohol, and removing the α-amine p... | 1,600 |
962 | 962 | 15,523,850 | 1,627 | The present invention relates to a method of controlling abiotic stress on warm-season turfgrass using an effective amount of acibenzolar-s-methyl. | 1. A method for controlling or suppressing abiotic stress in warm-season turfgrass, comprising applying to the turfgrass or to the locus of the turfgrass, a turf quality improving amount of acibenzolar-S-methyl at a rate between about 32 and 96 g/ha. 2. The method of claim 1, wherein the warm season turfgrass is Bermud... | The present invention relates to a method of controlling abiotic stress on warm-season turfgrass using an effective amount of acibenzolar-s-methyl.1. A method for controlling or suppressing abiotic stress in warm-season turfgrass, comprising applying to the turfgrass or to the locus of the turfgrass, a turf quality imp... | 1,600 |
963 | 963 | 15,757,424 | 1,612 | The present invention concerns a composition under the form of aqueous gel for caring for and/or making up keratin materials comprising, in a physiologically acceptable medium, a) one aqueous phase; and b) at least one hydrophilic gelling agent, and c) at least microcapsules comprising:—an inner core comprising at leas... | 1. A composition, in the form of aqueous gel, comprising, in a physiologically acceptable medium;
a) one aqueous phase; b) at least one hydrophilic gelling agent; and c) at least microcapsules comprising:
an inner core comprising at least a dispersion of at least one reflective agent in at least one oil, and
at least o... | The present invention concerns a composition under the form of aqueous gel for caring for and/or making up keratin materials comprising, in a physiologically acceptable medium, a) one aqueous phase; and b) at least one hydrophilic gelling agent, and c) at least microcapsules comprising:—an inner core comprising at leas... | 1,600 |
964 | 964 | 15,023,858 | 1,642 | Provided herein are antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life, as well as compositions and... | 1. A method of resensitizing a tumor or tumor cell in a subject to a HER targeted therapy, comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof which specifically binds to an epitope within the extracellular domain of HER3, wherein
(i) the antibod... | Provided herein are antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life, as well as compositions and... | 1,600 |
965 | 965 | 16,165,813 | 1,647 | Modified bovine G-CSF polypeptides and uses thereof are provided. | 1-67. (canceled) 68. A method of treating an animal having a disorder modulated by bG-SCF comprising administering to the animal a therapeutically-effective amount of a bG-CSF polypeptide comprising the sequence of SEQ ID NO: 1 or SEQ ID NO: 2, wherein position 133 of SEQ ID NO: 1 or position 134 of SEQ ID NO: 2 is sub... | Modified bovine G-CSF polypeptides and uses thereof are provided.1-67. (canceled) 68. A method of treating an animal having a disorder modulated by bG-SCF comprising administering to the animal a therapeutically-effective amount of a bG-CSF polypeptide comprising the sequence of SEQ ID NO: 1 or SEQ ID NO: 2, wherein po... | 1,600 |
966 | 966 | 15,152,956 | 1,616 | The present disclosure relates to methods for treating hair with lactones. The lactones form a covalent thio-ester bond with free thiols groups on chemically treated hair, and thereby impart a “repairing” or “conditioning” effect to the hair, for example, by making the hair more hydrophobic. Typically, after hair has b... | 1. A method for treating hair having two or more free thiol groups, comprising applying to the hair a composition comprising one or more lactones in an effective amount to covalently bind the free thiol groups. 2. The method of claim 1, wherein the lactones and the free thiol groups form a thio-ester bond. 3. The metho... | The present disclosure relates to methods for treating hair with lactones. The lactones form a covalent thio-ester bond with free thiols groups on chemically treated hair, and thereby impart a “repairing” or “conditioning” effect to the hair, for example, by making the hair more hydrophobic. Typically, after hair has b... | 1,600 |
967 | 967 | 15,063,211 | 1,662 | The present invention is directed to methods and compositions to eliminate cold storage-induced sweetening of potato or sweet potato. The invention is accomplished in part by silencing the vacuolar acid invertase gene using RNAi technology. The resulting potatoes withstand cold storage without significant hexogenesis, ... | 1-20. (canceled) 21. A transgenic plant cell comprising a nucleic acid sequence having at least 95% sequence identity to a sequence selected from the group consisting of SEQ ID NO:9, 10, 11, 23, and 24, wherein a sense copy and an antisense copy of the nucleic acid sequence are on the same strand of a double-stranded v... | The present invention is directed to methods and compositions to eliminate cold storage-induced sweetening of potato or sweet potato. The invention is accomplished in part by silencing the vacuolar acid invertase gene using RNAi technology. The resulting potatoes withstand cold storage without significant hexogenesis, ... | 1,600 |
968 | 968 | 14,132,533 | 1,627 | The disclosure relates to methods, compositions, and kits for treatment of parasite-mediated disease. In one embodiment, the disclosure relates to compounds, compositions, methods and kits for the treatment of malaria. In still another embodiment, the disclosure relates to a method for treating malaria comprising the u... | 1. A method for treating malaria comprising:
(a) identifying a patient in need of treatment from malaria; and (b) administering to said patient a therapeutically effective amount of a Syk kinase inhibitor to treat malaria. 2. The method of claim 1, wherein said malaria is selected from the group consisting of: Quartan ... | The disclosure relates to methods, compositions, and kits for treatment of parasite-mediated disease. In one embodiment, the disclosure relates to compounds, compositions, methods and kits for the treatment of malaria. In still another embodiment, the disclosure relates to a method for treating malaria comprising the u... | 1,600 |
969 | 969 | 15,738,194 | 1,619 | The present invention relates to a purgative composition for cleansing an intestinal tract and, specifically, to a purgative composition for cleansing an intestinal tract, the composition containing 40-60 g of polyethylene glycol, 10-28 g of sorbitol, and 1-10 mg of sodium picosulfate, on the basis of 100 ml of the com... | 1. A purgative composition for cleansing an intestinal tract comprising polyethylene glycol, sorbitol and sodium picosulfate. 2. The purgative composition for cleansing an intestinal tract according to claim 1, wherein the composition comprises 40 to 60 g of polyethylene glycol, 10 to 28 g of sorbitol, and 1 to 10 mg o... | The present invention relates to a purgative composition for cleansing an intestinal tract and, specifically, to a purgative composition for cleansing an intestinal tract, the composition containing 40-60 g of polyethylene glycol, 10-28 g of sorbitol, and 1-10 mg of sodium picosulfate, on the basis of 100 ml of the com... | 1,600 |
970 | 970 | 14,775,144 | 1,615 | The present invention is directed to alkoxylated alcohol alkyl ethers. In some embodiments, these ethers include a very short chain ether end cap, such as a methyl or ethyl group. In some embodiments, the long chain fatty alcohol used is unsaturated and/or branched. In some embodiments, a compound of the invention incl... | 1. A compound having Formula X:
R1O-A-R2 (Formula X)
wherein:
i) A is one selected from the group consisting of:
a) (PO)n, where P is a branched alkyl group having 3 carbons and n is an integer ranging from 2 to 10;
b) (EO)m, where E is an alkyl group having 2 carbons and m is an integer ranging from 2 to 6; and
c) ... | The present invention is directed to alkoxylated alcohol alkyl ethers. In some embodiments, these ethers include a very short chain ether end cap, such as a methyl or ethyl group. In some embodiments, the long chain fatty alcohol used is unsaturated and/or branched. In some embodiments, a compound of the invention incl... | 1,600 |
971 | 971 | 13,511,768 | 1,639 | The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As w... | 1. The hemitartrate salt of a compound represented by the following structural formula:
wherein the salt is an amorphous salt. 2. The hemitartrate salt of a compound represented by the following structural formula:
wherein at least 70% by weight of the salt is crystalline. 3. The hemitartrate salt... | The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As w... | 1,600 |
972 | 972 | 15,436,919 | 1,649 | The invention relates to compounds which activate the BASIGIN signalling pathway, preferably agonists of BASIGIN, for the treatment of neurodegenerative disorders. | 1-9. (canceled) 10. A method for screening a drug for the treatment of a retinal neurodegenerative disorder comprising the steps consisting of:
a) providing a plurality of neurons expressing BASIGIN on their surface, wherein said neurons are cone photoreceptors; b) incubating said neurons with a candidate compound; c) ... | The invention relates to compounds which activate the BASIGIN signalling pathway, preferably agonists of BASIGIN, for the treatment of neurodegenerative disorders.1-9. (canceled) 10. A method for screening a drug for the treatment of a retinal neurodegenerative disorder comprising the steps consisting of:
a) providing ... | 1,600 |
973 | 973 | 15,497,122 | 1,633 | Methods for introducing exogenous material into a cell are provided, which include exposing the cell to a transient decrease in pressure in the presence of the exogenous material. Also provided are devices for performing the method of the invention. | 1. A method for introducing an exogenous material into a cell, comprising exposing said cell to a transient decrease in pressure and unsteady flow in the presence of said exogenous material to thereby introduce said exogenous material into said cell. 2. The method of claim 1, wherein the cell is viable after being expo... | Methods for introducing exogenous material into a cell are provided, which include exposing the cell to a transient decrease in pressure in the presence of the exogenous material. Also provided are devices for performing the method of the invention.1. A method for introducing an exogenous material into a cell, comprisi... | 1,600 |
974 | 974 | 15,510,278 | 1,653 | An enzymatic processing plant for continuous flow-based enzymatic processing of organic molecules, comprises an enzymatic processing area, wherein the enzymatic processing area comprises a turbulence-generating pipe with a repeatedly changing centre-line and/or a repeatedly changing cross-section, for generating turbul... | 1. An enzymatic processing plant for continuous flow-based enzymatic processing of organic molecules, comprising an enzymatic processing area, wherein the enzymatic processing area comprises a turbulence-generating pipe with a repeatedly changing centre-line and/or a repeatedly changing cross-section, for generating tu... | An enzymatic processing plant for continuous flow-based enzymatic processing of organic molecules, comprises an enzymatic processing area, wherein the enzymatic processing area comprises a turbulence-generating pipe with a repeatedly changing centre-line and/or a repeatedly changing cross-section, for generating turbul... | 1,600 |
975 | 975 | 15,577,783 | 1,612 | The present invention relates to an oral care composition having an anionic surfactant, a cationic or amphoteric surfactant, and a potassium salt, wherein the oral care composition does not include a non-ionic surfactant. | 1. An oral care composition comprising:
a) an anionic surfactant; b) a cationic or amphoteric surfactant; and c) a potassium salt; wherein the oral care composition does not comprise a non-ionic surfactant. 2. The oral care composition of claim 1, further comprising a thickener. 3. The oral care composition of claim 2,... | The present invention relates to an oral care composition having an anionic surfactant, a cationic or amphoteric surfactant, and a potassium salt, wherein the oral care composition does not include a non-ionic surfactant.1. An oral care composition comprising:
a) an anionic surfactant; b) a cationic or amphoteric surfa... | 1,600 |
976 | 976 | 15,145,337 | 1,612 | A preparation in the form of a powder containing: (a) at least one carotenoid, (b) at least one modified starch, and (c) sucrose; wherein the at least one carotenoid is present in the powder in an amount of 1 to 25% by weight, based on the weight of the powder; and wherein the at least one carotenoid and the sucrose ar... | 1-20. (canceled) 21. A preparation in powder form comprising:
(a) at least one carotenoid, (b) at least one modified starch, and (c) sucrose; wherein the at least one carotenoid is present in the powder in an amount of 1 to 25% by weight, based on the weight of the powder; and wherein the at least one carotenoid and th... | A preparation in the form of a powder containing: (a) at least one carotenoid, (b) at least one modified starch, and (c) sucrose; wherein the at least one carotenoid is present in the powder in an amount of 1 to 25% by weight, based on the weight of the powder; and wherein the at least one carotenoid and the sucrose ar... | 1,600 |
977 | 977 | 15,803,967 | 1,653 | The present invention discloses the method of preparation and use of soft tissue membranous structures into slip resistant membranes with regularly spaced surface projections on one side and concave depressions on the other side with perforations or without perforations which enhance vascular ingrowth and tissue incorp... | 1. A method of making smooth two-sided wetted or non-dried biological membranes into three-dimensional membrane structures with regularly or irregularly spaced surface concave depressions on an at least first side and projections on at least the opposite second side, the method comprising the steps of:
acquiring a smoo... | The present invention discloses the method of preparation and use of soft tissue membranous structures into slip resistant membranes with regularly spaced surface projections on one side and concave depressions on the other side with perforations or without perforations which enhance vascular ingrowth and tissue incorp... | 1,600 |
978 | 978 | 15,325,472 | 1,642 | The invention features methods, devices, and kits for predicting the responsiveness of a cancer patient (e.g., a breast cancer patient, such as a grade 1, 2, or 3 breast cancer patient) to anthracycline treatment by determining the expression levels of four chromosomal instability (CIN) genes including HDGF, KIAA0286, ... | 1. A method of predicting the responsiveness of a cancer patient to anthracycline treatment comprising
a) determining the level of expression of at least one biomarker selected from the group consisting of HDGF, KIAA0286, RFC4, and MSH6 in a sample from the cancer patient, and b) i) comparing the level of expression of... | The invention features methods, devices, and kits for predicting the responsiveness of a cancer patient (e.g., a breast cancer patient, such as a grade 1, 2, or 3 breast cancer patient) to anthracycline treatment by determining the expression levels of four chromosomal instability (CIN) genes including HDGF, KIAA0286, ... | 1,600 |
979 | 979 | 16,289,416 | 1,615 | The present disclosure generally relates to film-forming compositions and capsules formed from such compositions, including processes for using such compositions to make capsules. In some embodiments, the film-forming compositions are free of animal products and carrageenan. | 1. A film-forming composition, the composition comprising:
(a) from 1 to 60 percent by weight of a hydroxyalkylated plant starch, a plant sugar, or a combination thereof; (b) from 1 to 30 percent by weight agar; and (c) from 30 to 80 percent by weight water; wherein the percents by weight are based on the total weight ... | The present disclosure generally relates to film-forming compositions and capsules formed from such compositions, including processes for using such compositions to make capsules. In some embodiments, the film-forming compositions are free of animal products and carrageenan.1. A film-forming composition, the compositio... | 1,600 |
980 | 980 | 13,355,768 | 1,618 | Solid pharmaceutical dosage form for the release of nicotine in the oral cavity comprising a core encapsulated by at least one film coating, wherein the core comprises nicotine and wherein the film coating comprises at least one film-forming polymer and at least one component for reduction of one or more organoleptical... | 1. A solid pharmaceutical dosage form comprising a core encapsulated by at least one film coating, wherein the core comprises nicotine and the film coating comprises at least one film-forming polymer and at least one component for reduction of one or more organoleptically disturbing sensations, and wherein the at least... | Solid pharmaceutical dosage form for the release of nicotine in the oral cavity comprising a core encapsulated by at least one film coating, wherein the core comprises nicotine and wherein the film coating comprises at least one film-forming polymer and at least one component for reduction of one or more organoleptical... | 1,600 |
981 | 981 | 15,568,206 | 1,627 | Disclosed are methods of treating an ibrutinib-resistant disease in a mammal with a compound of Formula (I): wherein R is described herein. In certain embodiments, a compound of Formula (I) inhibits the activity of a variant Btk, providing a method of treating ibrutinib-resistant diseases, such as ibrutinib-resistant l... | 1. A method of treating an ibrutinib-resistant disease in a mammal, the method comprising administering an effective amount of a compound of Formula (I):
wherein R is hydrogen, —CH2OP(O)(O−)2X− 2, or —CH2OP(O)(O−)2Y2+, and each X is independently a hydrogen ion or a monovalent cation, and Y2+ is a divalent c... | Disclosed are methods of treating an ibrutinib-resistant disease in a mammal with a compound of Formula (I): wherein R is described herein. In certain embodiments, a compound of Formula (I) inhibits the activity of a variant Btk, providing a method of treating ibrutinib-resistant diseases, such as ibrutinib-resistant l... | 1,600 |
982 | 982 | 14,645,276 | 1,647 | Methods of treating an autoimmune disease such as rheumatoid arthritis, methods of increasing apoptosis of pro-inflammatory immune cells or synoviocytes, methods of increasing the quantity of the anti-inflammatory regulatory T cells, and methods of slowing the progression of inflammation in a subject include systemical... | 1. A method of treating an autoimmune disease, of increasing apoptosis of pro-inflammatory immune cells or synoviocytes, or reducing or slowing the progression of inflammation, comprising systemically administering a subject with the autoimmune disease a pharmaceutical composition comprising an effective amount of TRAI... | Methods of treating an autoimmune disease such as rheumatoid arthritis, methods of increasing apoptosis of pro-inflammatory immune cells or synoviocytes, methods of increasing the quantity of the anti-inflammatory regulatory T cells, and methods of slowing the progression of inflammation in a subject include systemical... | 1,600 |
983 | 983 | 15,606,042 | 1,632 | A method is used for making an artificial micro-gland by taxis. A monodisperse multiple emulsion is produced with a first fluid; a second fluid confined within the first fluid; a third fluid within the second fluid. Interfaces between the fluids permit living cells dispersed in the one of the fluids to migrate towards ... | 1. A method of making an artificial micro-gland by taxis, the artificial micro-gland comprising a continuous membrane of living cells, the continuous membrane defining an enclosed volume, the enclosed volume comprising a reservoir serving as a bioreactor, the method comprising the steps of:
producing a monodisperse mul... | A method is used for making an artificial micro-gland by taxis. A monodisperse multiple emulsion is produced with a first fluid; a second fluid confined within the first fluid; a third fluid within the second fluid. Interfaces between the fluids permit living cells dispersed in the one of the fluids to migrate towards ... | 1,600 |
984 | 984 | 14,806,802 | 1,633 | A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen c... | 1. A transgenic non-human mammal comprising a heterologous immunoglobulin heavy chain locus comprising human VH gene segments, one or more human D gene segments, human J gene segments, and rat constant region gene segments, wherein the human VH gene segments comprise VH1-69, VH4-59, VH3-53, VH3-49, VH4-34, VH3-48, VH3-... | A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen c... | 1,600 |
985 | 985 | 12,783,477 | 1,641 | The present invention refers to a flow-through method of functionalizing an inner surface of a microfluidic device. The method can comprise transporting a silanizing solution through the microfluidic device to silanize the inner surface of the microfluidic device. The method can further comprise reacting the silanized ... | 1. A flow-through method of functionalizing an inner surface of a microfluidic device, wherein the method comprises:
transporting a silanizing solution through the microfluidic device to silanize the inner surface of the microfluidic device; and reacting the silanized surface with an oxidized polysaccharide to bind the... | The present invention refers to a flow-through method of functionalizing an inner surface of a microfluidic device. The method can comprise transporting a silanizing solution through the microfluidic device to silanize the inner surface of the microfluidic device. The method can further comprise reacting the silanized ... | 1,600 |
986 | 986 | 15,077,373 | 1,627 | The present application relates to pharmaceutical compositions and methods for treatment of urogenital diseases and bone metastasis in a human, which pharmaceutical composition contains an effective amount of arsenous acid alkaline or earth alkaline metal salt and/or a pharmaceutically acceptable adjuvant. According to... | 1. A method of treating multiple myeloma in a patient comprising administering a composition comprising a therapeutically effective amount of sodium meta arsenite to the patient. 2. The method of claim 1, wherein the sodium meta arsenite is administered orally. 3. The method of claim 1, wherein the therapeutically effe... | The present application relates to pharmaceutical compositions and methods for treatment of urogenital diseases and bone metastasis in a human, which pharmaceutical composition contains an effective amount of arsenous acid alkaline or earth alkaline metal salt and/or a pharmaceutically acceptable adjuvant. According to... | 1,600 |
987 | 987 | 15,615,423 | 1,627 | The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity. | 1. A method of antagonizing 5-HT7 and 5HT1B receptor activity in a patient suffering from ADHD, consisting of administering to the patient in need thereof a therapeutically effective amount of viloxazine, wherein the administration antagonizes both receptors. 2. The method of claim 1, wherein the therapeutically effect... | The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.1. A method of antagonizing 5-HT7 and 5HT1B receptor activity in a patient suffering from ADHD, consisting of... | 1,600 |
988 | 988 | 13,370,874 | 1,634 | Assay methods for preparing a biomolecule analyte includes hybridizing a sequence specific oligonucleotide probe to a biomolecule template and reacting the resulting analyte with a binding moiety. | 1. A method for preparing a biomolecule analyte, the method comprising:
a. providing a single-stranded DNA or RNA template; b. hybridizing a first plurality of identical, sequence specific oligonucleotide probes to the template, each probe having a 5′ end and a 3′ end, to thereby form an analyte having at least one sin... | Assay methods for preparing a biomolecule analyte includes hybridizing a sequence specific oligonucleotide probe to a biomolecule template and reacting the resulting analyte with a binding moiety.1. A method for preparing a biomolecule analyte, the method comprising:
a. providing a single-stranded DNA or RNA template; ... | 1,600 |
989 | 989 | 15,522,819 | 1,619 | The invention relates to a polymer comprising alkoxysilane groups, obtained by polycondensation of a diisocyanate, of a difunctional compound and of two different alkoxysilanes.
The invention also relates to a cosmetic composition comprising such a polymer and to a process for caring for or making up keratin mate... | 1. A process for preparing a polymer comprising alkoxysilane groups which can be obtained by polycondensation, comprising, in a first step, the reaction between:
(i) a diisocyanate of formula (I): OCN—Z—NCO (I) in which Z denotes a divalent hydrocarbon-based radical containing from 4 to 20 carbon atoms; and (ii) a difu... | The invention relates to a polymer comprising alkoxysilane groups, obtained by polycondensation of a diisocyanate, of a difunctional compound and of two different alkoxysilanes.
The invention also relates to a cosmetic composition comprising such a polymer and to a process for caring for or making up keratin mate... | 1,600 |
990 | 990 | 12,837,341 | 1,611 | The present invention relates to compositions for improving the efficacy of acetaminophen comprising a unit dose of acetaminophen and a therapeutic efficacy-enhancing amount of N-acetylcysteine, such that acetaminophen and N-acetylcysteine are present in the composition in a molar ratio of acetaminophen to N-acetyl cys... | 1. A composition for improving therapeutic efficacy of acetaminophen comprising
(a) a unit dose of acetaminophen and (b) a therapeutic efficacy-enhancing amount of N-acetyl cysteine, acetaminophen and N-acetylcysteine are present in the composition in a molar ratio of acetaminophen to N-acetyl cysteine ranging from abo... | The present invention relates to compositions for improving the efficacy of acetaminophen comprising a unit dose of acetaminophen and a therapeutic efficacy-enhancing amount of N-acetylcysteine, such that acetaminophen and N-acetylcysteine are present in the composition in a molar ratio of acetaminophen to N-acetyl cys... | 1,600 |
991 | 991 | 15,518,838 | 1,612 | An oral care composition comprising: (a) arginine, in free or salt form; (b) serine; (c) zinc oxide; and (d) zinc citrate. | 1. An oral care composition comprising:
a. arginine, in free or salt form; b. serine c. zinc oxide; and d. zinc citrate. 2. The oral care composition of claim 1, wherein the total concentration of zinc oxide and zinc citrate in the composition is from 0.2 weight % to 5 weight %, based on the total weight of the composi... | An oral care composition comprising: (a) arginine, in free or salt form; (b) serine; (c) zinc oxide; and (d) zinc citrate.1. An oral care composition comprising:
a. arginine, in free or salt form; b. serine c. zinc oxide; and d. zinc citrate. 2. The oral care composition of claim 1, wherein the total concentration of z... | 1,600 |
992 | 992 | 14,783,839 | 1,627 | The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one at the dosage of about 0.5 to 5 mg and more particularly 2 mg. Additionally, the invention is directed to the use o... | 1. A pharmaceutical composition comprising about 0.5 to 5 mg of (11β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one of formula
or a salt thereof. 2. The pharmaceutical composition according to claim 1 wherein the pharmaceutical composition comprises about 1 to 4 mg o... | The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one at the dosage of about 0.5 to 5 mg and more particularly 2 mg. Additionally, the invention is directed to the use o... | 1,600 |
993 | 993 | 15,622,682 | 1,619 | Provided is a cosmetic method by topical route for treating and/or preventing unpleasant human body odours, which comprises applying, to the surface of a human keratinous substance, a composition comprising, in a physiologically acceptable medium, at least one monounsaturated fatty acid or one of its salts and/or one o... | 1. A cosmetic method by oral route for treating and/or preventing unpleasant human body odours, which comprises ingesting an oral composition comprising, in a physiologically acceptable medium, at least one monounsaturated fatty acid or one of its salts and/or of its esters and/or one of its amides. 2. The cosmetic met... | Provided is a cosmetic method by topical route for treating and/or preventing unpleasant human body odours, which comprises applying, to the surface of a human keratinous substance, a composition comprising, in a physiologically acceptable medium, at least one monounsaturated fatty acid or one of its salts and/or one o... | 1,600 |
994 | 994 | 13,967,800 | 1,613 | Polyurea capsules that encapsulate active materials in polymeric walls resulting from the polymerization of an aromatic or aliphatic polyisocyanate and a cross-linking agent are provided as are consumer products containing said polyurea capsules and for methods for producing such capsules. | 1. A method for preparing a polyurea capsule composition comprising
(a) preparing an oil phase comprising an active material and a polyisocyanate; (b) preparing a surfactant solution; (c) emulsifying the oil phase into the surfactant solution to form a fragrance emulsion; (d) adding a cross-linking agent to the fragran... | Polyurea capsules that encapsulate active materials in polymeric walls resulting from the polymerization of an aromatic or aliphatic polyisocyanate and a cross-linking agent are provided as are consumer products containing said polyurea capsules and for methods for producing such capsules.1. A method for preparing a po... | 1,600 |
995 | 995 | 13,492,173 | 1,627 | Disclosed is a method of preparing a personal care composition wherein the composition comprising a dual cationic surfactant system of a mono-alkyl amine salt and di-alkyl cationic surfactant, high melting point fatty compounds and soluble salts, and wherein the method comprising the following steps: preparing oil phas... | 1. A method of preparing a personal care composition,
wherein the composition comprises: a cationic surfactant system comprising a mono-alkyl amine salt cationic surfactant and a di-alkyl cationic surfactant; a high melting point fatty compound; and an aqueous carrier, wherein the method comprises the steps: (1) prepar... | Disclosed is a method of preparing a personal care composition wherein the composition comprising a dual cationic surfactant system of a mono-alkyl amine salt and di-alkyl cationic surfactant, high melting point fatty compounds and soluble salts, and wherein the method comprising the following steps: preparing oil phas... | 1,600 |
996 | 996 | 14,321,392 | 1,618 | The invention relates to a process for preparing PCL-comprising microparticles, to microparticles obtainable by said process, to gel hence obtained and to several uses of the gel such as for the preparation of a medicament for treating a skin abnormality or disfigurement, and/or for controlling bladder function and/or ... | 1-15. (canceled) 16. A process for preparing polycaprolactone (PCL)-comprising microparticles, wherein the process comprises:
(a) solubilizing a PCL polymer in a solvent to form a PCL polymer solution, (b) mixing the PCL polymer solution with a liquid comprising a surfactant, said liquid having a viscosity between abou... | The invention relates to a process for preparing PCL-comprising microparticles, to microparticles obtainable by said process, to gel hence obtained and to several uses of the gel such as for the preparation of a medicament for treating a skin abnormality or disfigurement, and/or for controlling bladder function and/or ... | 1,600 |
997 | 997 | 15,686,919 | 1,628 | The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonist for the facilitation of emergence from general anesthesia. | 1-48. (canceled) 49. A method comprising:
administering to a subject a therapeutically effective amount of an alpha 7 nicotinic acetylcholine receptor (α7 nAChR) agonist, in free base form or acid addition salt form, thereby promoting wakefulness in the subject, wherein the α7 nAChR agonist is a compound of formula (I)... | The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonist for the facilitation of emergence from general anesthesia.1-48. (canceled) 49. A method comprising:
administering to a subject a therapeutically effective amount of an alpha 7 nicotinic acetylcholine receptor (α7 nAChR) agonist, ... | 1,600 |
998 | 998 | 12,058,209 | 1,629 | This invention relates to oral care compositions comprising an effective amount of a basic amino acid in free or salt form, together with an antibacterial agent, and to methods of using and of making such compositions. | 1. An oral care composition comprising
a. an effective amount of a basic amino acid, in free or salt form; b. an effective amount of an antibacterial agent. 2. The composition of claim 1 further comprising an anionic surfactant; an effective amount of a fluoride source; and/or an anionic polymer. 3. A composition accor... | This invention relates to oral care compositions comprising an effective amount of a basic amino acid in free or salt form, together with an antibacterial agent, and to methods of using and of making such compositions.1. An oral care composition comprising
a. an effective amount of a basic amino acid, in free or salt f... | 1,600 |
999 | 999 | 15,532,185 | 1,699 | The present invention relates to a method for detecting an aggregate form of an aggregate-forming polypeptide in a biosample, comprising the steps of: (a) spiking, in a biosample to be analyzed, (i) a monomeric or multimeric form of an aggregate-forming polypeptide, (ii) a hydrophobic deleted derivative of the aggregat... | 1. A method for detecting an aggregate form of an aggregate-forming polypeptide in a biosample, the method comprising the steps of:
(a) spiking, with a biosample to be analyzed, (i) a monomeric or multimeric form of the aggregate-forming polypeptide, (ii) a hydrophobic deleted derivative of the aggregate-forming polype... | The present invention relates to a method for detecting an aggregate form of an aggregate-forming polypeptide in a biosample, comprising the steps of: (a) spiking, in a biosample to be analyzed, (i) a monomeric or multimeric form of an aggregate-forming polypeptide, (ii) a hydrophobic deleted derivative of the aggregat... | 1,600 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.